| Luspatercept in patients with lower-risk myelodysplastic syndromes P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ... New England Journal of Medicine 382 (2), 140-151, 2020 | 445 | 2020 |
| The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ... haematologica 93 (9), 1301-1309, 2008 | 369 | 2008 |
| Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification S Carrancio, N López-Holgado, FM Sánchez-Guijo, E Villarón, V Barbado, ... Experimental hematology 36 (8), 1014-1021, 2008 | 213 | 2008 |
| Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial JA Pérez-Simon, O López-Villar, EJ Andreu, J Rifón, S Muntion, ... haematologica 96 (7), 1072, 2011 | 205 | 2011 |
| Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome O Lopez-Villar, JL Garcia, FM Sanchez-Guijo, C Robledo, EM Villarón, ... Leukemia 23 (4), 664-672, 2009 | 184 | 2009 |
| Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation JA Pérez‐Simón, M Díez‐Campelo, R Martino, S Brunet, Á Urbano, ... British journal of haematology 130 (3), 394-403, 2005 | 147 | 2005 |
| Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation JA Perez-Simon, D Caballero, M Diez-Campelo, R Lopez-Perez, ... Leukemia 16 (8), 1423-1431, 2002 | 134 | 2002 |
| Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation JA Pérez-Simón, M Díez-Campelo, R Martino, A Sureda, D Caballero, ... Blood 102 (3), 1108-1113, 2003 | 133 | 2003 |
| Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease F Sánchez-Guijo, T Caballero-Velázquez, O López-Villar, A Redondo, ... Biology of Blood and Marrow Transplantation 20 (10), 1580-1585, 2014 | 132 | 2014 |
| Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy M Pérez‐Ilzarbe, M Díez‐Campelo, P Aranda, S Tabera, T Lopez, ... Transfusion 49 (9), 1901-1910, 2009 | 130 | 2009 |
| Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena EM Ocio, FM Sanchez‐Guijo, M Diez‐Campelo, C Castilla, OJ Blanco, ... American journal of hematology 78 (4), 302-305, 2005 | 121 | 2005 |
| Response to lenalidomide in myelodysplastic syndromes with del (5q): influence of cytogenetics and mutations M Mallo, M Del Rey, M Ibanez, MJ Calasanz, L Arenillas, MJ Larráyoz, ... British journal of haematology 162 (1), 74-86, 2013 | 115 | 2013 |
| Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients C Santamaría, S Muntión, B Rosón, B Blanco, O López-Villar, S Carrancio, ... haematologica 97 (8), 1218, 2012 | 108 | 2012 |
| Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of … JA Pérez-Simón, C Encinas, F Silva, MJ Arcos, M Díez-Campelo, ... Biology of Blood and Marrow Transplantation 14 (10), 1163-1171, 2008 | 103 | 2008 |
| Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents S Park, JF Hamel, A Toma, C Kelaidi, S Thépot, MD Campelo, V Santini, ... Journal of Clinical Oncology 35 (14), 1591-1597, 2017 | 100 | 2017 |
| Chronic graft-versus-host disease: Pathogenesis and clinical management JA Perez-Simon, I Sánchez-Abarca, M Diez-Campelo, D Caballero, ... Drugs 66, 1041-1057, 2006 | 99 | 2006 |
| Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study DP Steensma, P Fenaux, K Van Eygen, A Raza, V Santini, U Germing, ... Journal of clinical oncology: official journal of the American Society of …, 2021 | 97 | 2021 |
| Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML MA Sekeres, J Watts, A Radinoff, MA Sangerman, M Cerrano, PF Lopez, ... Leukemia 35 (7), 2119-2124, 2021 | 96 | 2021 |
| Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) L Sanoja-Flores, J Flores-Montero, JJ Garcés, B Paiva, N Puig, ... Blood cancer journal 8 (12), 117, 2018 | 94 | 2018 |
| Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy L Sanoja-Flores, J Flores-Montero, N Puig, T Contreras-Sanfeliciano, ... Blood, The Journal of the American Society of Hematology 134 (24), 2218-2222, 2019 | 88 | 2019 |
